Does Aetna Cover Ozempic?

Aetna's General Coverage Policy for Ozempic

Aetna classifies Ozempic (semaglutide injection, 0.25 mg, 0.5 mg, 1 mg, and 2 mg doses) as a covered medication for adults with type 2 diabetes mellitus on the majority of its commercial, exchange, and Medicare Advantage Part D formularies. The drug sits on Aetna's specialty tier, which means prior authorization is mandatory before the pharmacy will fill the prescription.

Coverage hinges on the FDA-approved indication. The FDA approved Ozempic in December 2017 specifically as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes. Aetna's clinical policy bulletins mirror this label closely. If the prescriber submits a prior authorization request citing a confirmed type 2 diabetes diagnosis with a recent hemoglobin A1C value, the request enters Aetna's standard review pathway. Without that diagnosis code (ICD-10 E11.x), the claim is almost certain to be rejected at the pharmacy level.

A critical distinction: Ozempic is not FDA-approved for chronic weight management. That indication belongs to Wegovy (semaglutide 2.4 mg), a separate product with its own NDC codes and formulary placement. Aetna adjudicates the two products under different clinical policy bulletins. Prescribers who write Ozempic for obesity without a concurrent type 2 diabetes diagnosis will receive a denial.

Prior Authorization Requirements

Aetna requires prior authorization for Ozempic across virtually all plan types. The process typically takes 24 to 72 hours for a standard request, though urgent requests tied to active hyperglycemia may receive a faster turnaround.

Aetna's published precertification criteria generally require the prescriber to document three things. First, a confirmed diagnosis of type 2 diabetes. Second, a recent A1C result (most plans specify a value of 7.0% or higher, though some Aetna plans set the threshold at 6.5%). Third, evidence that the patient has tried and failed, or has a documented contraindication to, metformin, which remains the first-line pharmacotherapy recommended by the American Diabetes Association's Standards of Care [1].

Many Aetna plans also enforce a broader step-therapy protocol. This means metformin alone is not sufficient. The patient may need documentation showing inadequate glycemic control on metformin plus at least one additional oral agent (a sulfonylurea, SGLT2 inhibitor, or DPP-4 inhibitor) before the plan approves a GLP-1 receptor agonist. The specific step requirements vary by plan document, so checking the member's Summary of Benefits is essential before assuming a two-drug failure is enough.

The prior auth submission typically goes through Aetna's pharmacy benefit manager. Prescribers can submit electronically via CoverMyMeds or by fax using Aetna's precertification request form. Include the following with every submission: the patient's most recent A1C lab result (dated within 90 days), a medication history showing prior oral agent trials with dates and doses, the prescriber's clinical rationale for choosing semaglutide over formulary-preferred alternatives, and the target Ozempic dose.

Step Therapy: What Aetna Expects You to Try First

Step therapy is the most common reason Ozempic prior authorizations are denied on Aetna plans. The insurer requires documentation that the patient progressed through lower-cost diabetes medications before advancing to a GLP-1 receptor agonist.

The ADA's 2024 Standards of Care recommend metformin as first-line therapy for most adults with type 2 diabetes, with GLP-1 receptor agonists recommended as add-on therapy for patients who have established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, regardless of A1C [2]. Aetna's formulary design reflects this tiered approach but applies it more broadly.

On a typical Aetna commercial plan, step therapy requires:

Step 1: Metformin at maximally tolerated dose (usually 1,500 to 2,000 mg daily) for at least 90 days.

Step 2: Addition of a second oral agent. Aetna plans commonly prefer a sulfonylurea (glipizide, glimepiride) or an SGLT2 inhibitor (empagliflozin, dapagliflozin) at this stage.

Step 3: If A1C remains above target after dual oral therapy, the plan may approve a GLP-1 receptor agonist. Some Aetna plans prefer dulaglutide (Trulicity) or liraglutide (Victoza) over Ozempic at this step, which could trigger an additional coverage review.

Patients with true metformin intolerance (documented GI side effects at low doses, lactic acidosis risk factors, or eGFR <30 mL/min/1.73m²) can request a step-therapy exception. Aetna grants these exceptions when the prescriber provides clinical documentation of the contraindication. A simple note saying "patient prefers not to take metformin" will not satisfy the exception criteria.

What Ozempic Costs on Aetna Plans

Out-of-pocket costs vary significantly depending on the Aetna plan type, formulary tier, and whether the member has met their deductible.

Ozempic's wholesale acquisition cost is approximately $935.77 for a single 1 mg monthly pen, according to Novo Nordisk's pricing disclosures. On Aetna commercial plans where Ozempic sits on a preferred specialty tier, members typically pay a copay between $25 and $150 per month after meeting their annual deductible. On non-preferred tiers or plans with coinsurance instead of flat copays, the cost can reach $200 to $400 per month.

For Aetna Medicare Advantage Part D plans, coverage follows CMS formulary rules. Ozempic is covered for type 2 diabetes under Part D. In 2025, the Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D spending applies, meaning Medicare Advantage members on Aetna plans will not pay more than $2,000 total per year across all covered Part D drugs [3]. Once a member hits that cap, cost-sharing drops to $0 for the remainder of the plan year. This is a significant change from prior years where the coverage gap ("donut hole") could push monthly costs above $500.

Novo Nordisk offers a patient savings card for commercially insured patients that can reduce copays to as little as $25 per fill for up to 24 months, with a maximum benefit per fill. This card does not apply to government-funded insurance (Medicare, Medicaid, Tricare). Uninsured patients may qualify for Novo Nordisk's Patient Assistance Program, which provides the medication at no cost for eligible applicants with household incomes below 400% of the federal poverty level.

Why Aetna Denies Ozempic Claims (and How to Appeal)

Denials happen frequently with GLP-1 receptor agonists. Understanding the most common denial reasons gives patients and prescribers a framework for successful appeals.

Denial reason 1: Off-label use. Ozempic prescribed for weight loss without a type 2 diabetes diagnosis will be denied. The appeal strategy here is limited unless the patient has a concurrent T2D diagnosis. For weight management, the prescriber should consider submitting a prior auth for Wegovy instead, which Aetna evaluates under a separate obesity coverage policy.

Denial reason 2: Incomplete step therapy. The prescriber did not document prior metformin use. The fix is straightforward: submit pharmacy claims data or chart notes showing metformin trial dates, doses, duration, and reason for discontinuation.

Denial reason 3: Missing or outdated labs. A1C values older than 90 days, or a missing A1C entirely, will trigger an automatic denial from Aetna's pharmacy benefit manager. Resubmit with a current lab result.

Denial reason 4: Preferred alternative available. Some Aetna plans prefer Trulicity (dulaglutide) over Ozempic as the first-line injectable GLP-1. If Ozempic is denied for this reason, the prescriber can either switch to the preferred agent or file a formulary exception request citing clinical reasons why Ozempic is medically necessary for the specific patient. The SUSTAIN-7 trial showed that semaglutide 1 mg produced a mean A1C reduction of 1.8% compared to 1.4% with dulaglutide 1.5 mg at 40 weeks (P<0.0001), which provides a clinical rationale for the exception request [4].

The appeal process follows a two-tier structure. The first-level internal appeal must be filed within 180 days of the denial. Aetna is required to respond within 30 days for standard appeals or 72 hours for expedited appeals involving active medical treatment. If the internal appeal is denied, the member can request an external review by an independent review organization (IRO). The external review decision is binding on Aetna.

Ozempic vs. Wegovy: Why the Distinction Matters for Aetna Coverage

Both products contain semaglutide. Both are manufactured by Novo Nordisk. They are not interchangeable from an insurance perspective.

Ozempic is FDA-approved for type 2 diabetes at doses of 0.25 mg (initiation), 0.5 mg, 1 mg, and 2 mg. Wegovy is FDA-approved for chronic weight management at doses of 0.25 mg through 2.4 mg in adults with BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity [5]. Aetna processes these through entirely separate clinical policy bulletins with different prior authorization criteria.

If a patient has both type 2 diabetes and obesity, Ozempic is the more straightforward coverage pathway on Aetna because diabetes medications have fewer coverage restrictions than anti-obesity medications. Many Aetna commercial plans exclude anti-obesity medications entirely, while very few exclude diabetes medications. A patient with T2D and a BMI of 32 is better served by an Ozempic prior auth citing diabetes as the indication than a Wegovy prior auth citing obesity.

For patients without diabetes who want GLP-1 therapy for weight loss, Aetna's coverage of Wegovy varies dramatically by employer plan. Large self-insured employers increasingly add obesity medication coverage, but many Aetna fully-insured small-group plans still exclude the entire anti-obesity medication class. The member's certificate of coverage (the plan document, not the formulary) is the definitive source for whether anti-obesity drugs are a covered benefit.

Medicare Advantage Through Aetna: Special Considerations

Medicare Part D covers Ozempic for type 2 diabetes but is prohibited by federal statute from covering drugs prescribed solely for weight loss or cosmetic purposes. This statutory exclusion applies regardless of which Medicare Advantage carrier administers the plan.

For Aetna Medicare Advantage members with type 2 diabetes, Ozempic coverage follows the same prior authorization pathway as commercial plans, with one major financial difference. The Inflation Reduction Act restructured Part D cost-sharing beginning in 2025, establishing a $2,000 annual out-of-pocket maximum for all Part D covered medications [3]. Before this change, Medicare beneficiaries in the catastrophic phase still owed 5% coinsurance with no cap, which could mean $500 or more per month for specialty-tier drugs like Ozempic.

Aetna Medicare Advantage plans also offer the Part D Senior Savings Model in some regions, which caps insulin copays at $35 per month. While this does not directly apply to Ozempic, it reflects the broader trend of CMS programs reducing diabetes medication costs.

One scenario catches many Medicare beneficiaries off guard. A patient starts Ozempic for type 2 diabetes, achieves an A1C below 6.5%, and the prescriber continues the medication for maintenance. Some Aetna Medicare plans flag this for re-review, questioning whether the drug is still medically necessary if the patient's diabetes "appears resolved." The prescriber should document that continued GLP-1 therapy is required to maintain glycemic control and that discontinuation would likely result in A1C rebound. The SUSTAIN-6 cardiovascular outcomes trial demonstrated that semaglutide reduced the risk of major adverse cardiovascular events (MACE) by 26% (HR 0.74, 95% CI 0.58-0.95) over 2.1 years in patients with type 2 diabetes at high cardiovascular risk, providing clinical justification for ongoing therapy beyond glycemic targets alone [6].

How to Check Your Specific Aetna Plan's Ozempic Coverage

Every Aetna plan is different. A colleague's Aetna coverage experience may not match yours. Here is how to verify your plan's specific terms.

Check the formulary first. Log in to Aetna.com, manage to "Find a Medication," and search for Ozempic. The result will show the tier placement, whether prior authorization is required, and any step therapy or quantity limits. If Ozempic does not appear on your formulary at all, the drug is either excluded from your plan or listed under a different tier structure that requires manual review.

Read the Summary of Benefits and Coverage (SBC). This document, available on Aetna.com or from your employer's HR department, shows your plan's specialty-tier copay or coinsurance percentage. It also lists any annual or lifetime maximums on prescription drug spending.

Call the number on your Aetna ID card. Ask specifically: "Is Ozempic on my formulary, and what is the prior authorization criteria for my plan?" The representative can pull up your plan's specific clinical policy and tell you exactly what documentation the prescriber needs to submit. Get the representative's name and a reference number for the call.

Ask your prescriber's office to run a real-time benefits check. Most electronic health record systems can query Aetna's formulary in real time, showing the expected copay and any PA requirements before the prescription is even sent to the pharmacy. This saves time and avoids surprise denials at the pharmacy counter.

According to ADA guidelines, GLP-1 receptor agonists like semaglutide should be considered early in the treatment algorithm for patients with type 2 diabetes who have indicators of high cardiovascular risk, heart failure, or chronic kidney disease [2]. If your clinical profile matches these criteria, your prescriber has a strong basis for the prior authorization request, and Aetna approval rates are highest when the submission explicitly references guideline-concordant prescribing.

Tips for Reducing Your Out-of-Pocket Cost on Aetna

Even with Aetna coverage, specialty-tier copays can strain monthly budgets. Several strategies can reduce what you actually pay.

Novo Nordisk's savings card brings commercially insured copays down to $25 per fill. The card is available at ozempic.com and activates automatically at participating pharmacies. It cannot be combined with government insurance.

If your Aetna plan places Ozempic on a non-preferred tier, your prescriber can submit a tier exception request arguing that the preferred alternative (often Trulicity) was tried and failed or is clinically inappropriate. A successful tier exception moves Ozempic to the preferred copay level. The SUSTAIN-7 head-to-head data showing semaglutide's superior A1C reduction and weight loss compared to dulaglutide supports these requests [4].

Specialty pharmacies designated by Aetna (like CVS Specialty or Aetna Specialty Pharmacy) often have lower copays than retail pharmacies for specialty-tier medications. Your plan may require you to use the designated specialty pharmacy after the first fill.

For Aetna Medicare Advantage members, the $2,000 annual Part D out-of-pocket cap means that even at full specialty-tier coinsurance, total annual spending on all Part D drugs is now capped. If you take multiple medications, you may hit that cap early in the year and pay $0 for Ozempic during the remaining months.

Patients who are denied coverage entirely and cannot afford the list price should contact Novo Nordisk's Patient Assistance Program at 1-866-310-7549 or through novocare.com. Eligibility is based on income, insurance status, and residency. Approved applicants receive Ozempic at no cost, shipped directly to their home or prescriber's office.